Skip to main content

Lorlatinib and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with lorlatinib.


lorlatinib food

Major Food Interaction

Do not consume grapefruit or grapefruit juice during treatment with lorlatinib. Grapefruit juice can significantly increase the blood levels and effects of lorlatinib, which may result in a greater risk of side effects. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data


High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

lorlatinib - hyperlipidemia

Increases in serum cholesterol and triglycerides have been reported in patients receiving lorlatinib. Grade 3 or 4 elevations in total cholesterol occurred in 17% and Grade 3 or 4 elevations in triglycerides occurred in 17% of the patients enrolled in a clinical trial with up to 80% percent of patients requiring initiation of lipid-lowering medications. Caution is advised in patients with hyperlipidemias. Monitor serum cholesterol and triglycerides before initiating treatment and 1 and 2 months after initiating, and periodically thereafter. Initiation or increase of the dose of lipid-lowering agents might be required on these patients.


  1. "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group (2018):

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

lorlatinib - hypertension

The use of lorlatinib might cause hypertension. It is recommended to assess and control blood pressure prior to treatment initiation. Caution should be exercised when treating patients with prior history of hypertension, uncontrolled hypertension, and those at risk. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment. Withhold and resume lorlatinib at a reduced dose or permanently discontinue treatment based on severity.


  1. "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group (2018):

Lorlatinib drug interactions

There are 488 drug interactions with lorlatinib.

Lorlatinib disease interactions

There are 8 disease interactions with lorlatinib which include:

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.